An imbalance of branched-chain amino acids (BCAAs) in the brain may result in neuropathological conditions, such as autism spectrum disorders. The L-type amino acid transporter 1 (LAT1), encoded by the solute carrier transporter 7a5 (Slc7a5) gene, is critical for maintaining normal levels of BCAAs in the brain. However, our understanding of the mechanisms that regulate the expression of LAT1/Slc7a5 in neurons is currently limited. Here, we demonstrate that hypoxic conditions result in upregulated expression of Slc7a5 in differentiated neuronal cells (Neuro2A cells induced to differentiate using all-trans retinoic acid). Mechanistically, hypoxia-induced expression of Slc7a5 is markedly reduced by short hairpin RNA (shRNA)-mediated knockdown of hypoxia-inducible factor 2a (HIF-2a), but not by shRNA targeting HIF-1a, in differentiated neuronal cells. Moreover, hypoxia increased the binding of HIF-2a to the proximal promoter of Slc7a5 in differentiated neuronal cells. These results indicate that hypoxia directly enhances the recruitment of HIF-2a to the proximal promoter of Slc7a5, resulting in its upregulated expression in differentiated neuronal cells. These findings indicate that Slc7a5 may be a novel gene responsive to hypoxia in a HIF-2a-dependent manner in differentiated neuronal cells.
An imbalance of branched-chain amino acids (BCAAs) in the brain may result in neuropathological conditions, such as autism spectrum disorders. The L-type amino acid transporter 1 (LAT1), encoded by the solute carrier transporter 7a5 (Slc7a5) gene, is critical for maintaining normal levels of BCAAs in the brain. However, our understanding of the mechanisms that regulate the expression of LAT1/Slc7a5 in neurons is currently limited. Here, we demonstrate that hypoxic conditions result in upregulated expression of Slc7a5 in differentiated neuronal cells (Neuro2A cells induced to differentiate using all-trans retinoic acid). Mechanistically, hypoxia-induced expression of Slc7a5 is markedly reduced by short hairpin RNA (shRNA)-mediated knockdown of hypoxia-inducible factor 2a (HIF-2a), but not by shRNA targeting HIF-1a, in differentiated neuronal cells. Moreover, hypoxia increased the binding of HIF-2a to the proximal promoter of Slc7a5 in differentiated neuronal cells. These results indicate that hypoxia directly enhances the recruitment of HIF-2a to the proximal promoter of Slc7a5, resulting in its upregulated expression in differentiated neuronal cells. These findings indicate that Slc7a5 may be a novel gene responsive to hypoxia in a HIF-2a-dependent manner in differentiated neuronal cells.
It is well recognized that amino acids are capable of regulating cellular function through the modulation of signaling pathways (e.g., the mechanistic target of rapamycin complex 1 [mTORC1]) in various cell types, including the main cell types characterizing the central nervous system (CNS), neurons, and glial cells [1] [2] [3] . Moreover, branched-chain amino acids (BCAAs) serve as precursors for the synthesis of neurotransmitter glutamate. Pathologically high levels of BCAAs, as observed in maple syrup urine disease, cause excessive glutamatergic signaling and neurological symptoms, such as cognitive dysfunctions, seizures, and hypotonia [4, 5] .
Moreover, it has been reported that mutations in the gene encoding branched-chain keto acid dehydrogenase kinase, the rate-limiting enzyme in the catabolic pathway of BCAAs, result in autism spectrum disorder (ASD) and fine motor coordination problems because of abnormally low levels of BCAAs in the serum and brain [6] .
Because a constant supply of BCAAs from the periphery is essential for the functions of the brain during development and its homeostasis, factors facilitating the uptake of BCAA may be critical for the proper functioning of the CNS. The L-type amino acid transporter 1 (LAT1), encoded by the solute carrier transporter 7a5 (Slc7a5) gene, forms a heterodimer with a type II glycoprotein, the heavy chain of the 4F2 cell-surface antigen (4F2hc/CD98), via a disulfide bond [7, 8] . It has been shown that LAT1 is expressed in the blood-brain barrier (BBB) for maintaining normal levels of BCAAs in the brain. Moreover, LAT1 deficiency in cerebral endothelial cells causes neurological and behavioral abnormalities associated with ASD [9] [10] [11] . Although the pivotal expression and crucial role of Slc7a5 in the BBB (particularly in endothelial cells) have been determined, there is limited evidence regarding the potential expression of Slc7a5 and molecular mechanisms underlying the regulation of its expression in neuronal cells under pathological conditions. Hypoxia-inducible factors (HIFs) are transcription factors that transcriptionally regulate a large number of genes involved in angiogenesis, glycogenesis, and cell survival, promoting adaptation to hypoxic/ischemic stress in response to low tissue oxygenation during ischemic stroke [12, 13] . HIFs are heterodimers, comprising one of the three major oxygen labile HIF-a subunits (HIF-1a, HIF-2a, or HIF-3a) and a constitutive HIF-1b subunit. Among these, the HIF-1a/HIF1b and HIF-2a/HIF-1b dimers are the primary factors regulating hypoxic transcriptional responses in most mammalian cells [14] .
In this study, we investigated whether Slc7a5 is regulated by hypoxia to mimic an ischemic stroke environment in neuronal cells, and the molecular mechanisms underlying the regulation of the expression of Slc7a5. 
Materials and methods

Culture of Neuro2A cells
Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from cells, followed by the synthesis of cDNA using reverse transcriptase and oligo-dT primers. Subsequently, the cDNA samples were used as templates for real-time PCR analysis, performed on an MX3005P
TM instrument (Agilent Technologies, Santa Clara, CA, USA), using specific primers for each gene ( Table 1 ). The expression levels of the genes examined were normalized using the Actb expression levels as an internal control for each sample [17] .
Retroviral short hairpin RNA (shRNA) vector and infection
The retroviral shRNA vector for HIF-1a was previously generated [18] , and the shRNA vector for HIF-2a was obtained from Sigma. Retroviral vectors were transfected into PLAT-E cells using the calcium carbonate method. Virus supernatants were collected 48 h after transfection, and the cells were subsequently infected with virus supernatants for 24 h in the presence of 4 lgÁmL À1 polybrene [19] .
Chromatin immunoprecipitation (ChIP) assay
ChIP experiments were performed according to the manufacturer's protocol [20] . Briefly, Neuro2A cells were incubated with 1% formaldehyde at room temperature for 20 min. After centrifugation of the crosslinked samples, the pellet Table 1 . List of primers used for qPCR in this study. was homogenized and subjected to sonication using lysis buffer. Immunoprecipitation was performed using the anti-HIF-1a (#sc-10790) (Santa Cruz, Dallas, TX, USA) and anti-HIF-2a (#ab199) (Abcam, Cambridge, UK) antibodies. DNA was extracted using phenol/chloroform, and PCR was performed using specific primers: (a) 5 0 -ACTTGTGAG-
Immunoblotting Cultured cells were solubilized in lysis buffer containing 1% Nonidet P-40 detergent. Samples were then subjected to SDS/PAGE, followed by transfer to polyvinylidene fluoride membranes and subsequent immunoblotting with antib-Actin (#sc-47778) (Santa Cruz), anti-p-p70S6K1 (#9234), and anti-p70S6K1 (#2708) (Cell Signaling Technology, Danvers, MA, USA).
Data analysis
All results are expressed as the mean AE standard error of the mean, and statistical significance was determined using the two-tailed, unpaired Student's t-test, or two-way analysis of variance using the Bonferroni post hoc test.
Results and Discussion
We initially determined the expression of Slc7a5 in response to hypoxia in cultured neuronal cells. Differentiated Neuro2A cells were exposed to hypoxia for 12 h; further, the expression of Slc7a5 was determined using qPCR. A marked upregulation in the expression of hypoxia-responsive genes, such as heme oxygenase-1 (Hmox1) and glucose transporter-1 (Glut1) (Fig. 1A) , was detected in these cells cultured under hypoxia for 12 h. Under this experimental condition, the expression of Slc7a5 was significantly increased by hypoxia in differentiated Neuro2A cells (Fig. 1B) . In addition to LAT1 (Slc7a5), three additional LATs have been identified, namely LAT2 (Slc7a8), LAT3 (Slc43a1), and LAT4 (Slc43a2) [21] . No marked upregulation was observed in the expression of Slc7a8 with hypoxia in differentiated Neuro2A cells, whereas significant decreases were observed in the expression of Slc43a1 and Slc43a2 (Fig. 1C) . In contrast, neither endoplasmic reticulum (ER) stressor tunicamycin at 0.1 lgÁmL À1 nor the oxidative stressor hydrogen peroxide (H 2 O 2 ) at 100 lM significantly affected Slc7a5 expression in differentiated Neuro2A cells (Fig. 1D) . These results indicate that the expression of Slc7a5 was selectively upregulated in differentiated Neuro2A cells by hypoxia but not by ER stressor and oxidative stressor. We subsequently investigated the regulation of hypoxia-induced Slc7a5 expression by HIF, a master transcriptional regulator of the adaptive response to hypoxia. Differentiated Neuro2A cells were retrovirally infected using shRNA for HIF-1a (shHif-1a) or HIF2a (shHif-2a), followed by culture under hypoxia for 12 h and subsequent determination of the expression of Slc7a5. We initially confirmed that the expression of Hif1a or Hif2a was significantly decreased in differentiated Neuro2A cells through retroviral infection using shHif-1a or shHif-2a, respectively, under both normoxia and hypoxia, without alteration of their expression by hypoxia in cells infected with shControl, shHif-1a, or shHif-2a ( Fig. 2A,B) . Under these experimental conditions, the expression of Slc7a5 was markedly increased by hypoxia in cells transfected with shControl. Additionally, a significant upregulation of Slc7a5 expression under hypoxia was observed in cells transfected with shHif-1a but not with shHif-2a. Moreover, the hypoxia-induced upregulation of the expression of Slc7a5 was completely blocked through infection with shHif-2a, but not with shHif-1a (Fig. 2C,D) . Collectively, the hypoxia-induced expression of Slc7a5 was regulated by the transcription factor HIF-2a in differentiated neuronal cells.
Computational analysis of the 5 0 -flanking region of the highly conserved mouse and human Slc7a5 genes identified one putative HIF-responsive element (HRE) (Fig. 3A) . Subsequently, we investigated the role of HIF recruitment to the promoter region of the Slc7a5 gene in the upregulation of the expression of Slc7a5 in differentiated Neuro2A cells under hypoxic conditions. The cells were exposed to hypoxia for 12 h, followed by immunoprecipitation using the anti-HIF-1a or anti-HIF-2a antibodies and PCR using primers (primers a and b indicated in Fig. 3A) to amplify a region containing the HRE of the Slc7a5 promoter. The recruitment of HIF-1a to the Slc7a5 promoter region was equally observed in differentiated Neuro2A cells under normoxia and hypoxia (Fig. 3B,C) . Alternatively, the recruitment of HIF-2a to the Slc7a5 promoter region was markedly increased through exposure to hypoxia in differentiated Neuro2A cells (Fig. 3B,C) . These results indicate that HIF-2a binds directly to the putative binding site located at the Slc7a5 promoter, leading to the upregulation of the expression of Slc7a5 under hypoxia in differentiated neuronal cells.
It has been previously shown that the activation of the HIF-2a pathway was reported to increase mTORC1 activity by upregulating expression of Slc7a5 in tumor cells and in lung tissue [22] . Accordingly, the finding that hypoxia induces Slc7a5 expression through HIF-2a in this study led us to examine whether hypoxia can increase mTORC1 activity in differentiated neuronal cells. The phosphorylated form of p70S6K1, a downstream marker of mTORC1, was markedly increased through exposure to hypoxia for 12 h in differentiated Neuro2A cells (Fig. 3D) , indicating that hypoxia induces not only Slc7a5 expression but also mTORC1 activation in differentiated neuronal cells.
Maintaining normal levels of BCAAs in the brain is critical for brain homeostasis. Abnormal levels of BCAAs lead to pathophysiological implications such as ASD. In addition to the uptake of BCAAs, LAT1 has been implicated in the delivery of pharmaceutical drugs into the brain, including L-DOPA and gabapentin, and thyroid hormones [23] [24] [25] . Therefore, LAT1 (Slc7a5), expressed at the surface of neuronal cells, may play a crucial role in drug delivery and hormonal input into the brain, in addition to amino acid sensing.
It should be noted that hypoxia decreased mRNA expression of Slc43a1 and Slc43a2, which do not contain conserved HRE between mouse and human, in differentiated Neuro2A cells. Although the exact mechanism underlying the downregulation of Slc43a1 and Slc43a2 should be elucidated, in this study, we focused on the regulatory mechanism by which hypoxia/HIF axis controls the expression of Slc7a5.
In this study, we demonstrated that the amino acid transporter gene Slc7a5 may be a novel gene responsive to hypoxia in a HIF-2a-dependent manner in differentiated neuronal cells. Slc7a5 global knockout in mice is embryonically lethal at E9.5-10.5. Therefore, the in vivo vital role of Slc7a5 expressed by neurons in the development, homeostasis, and pathology of the CNS remains highly unclear [26] . mTORC1 is implicated in neurodegenerative and neuropsychiatric diseases as well as in various physiological brain functions, including learning, memory, and synaptic plasticity [27] . Additional studies are warranted to determine the crucial role of upregulated Slc7a5 in neuronal functions by hypoxic condition. However, the fact that hypoxia increased both Slc7a5 expression through HIF-2a and mTORC1 activity in differentiated neuronal cells suggests one possible but hitherto unidentified speculation that hypoxia/HIF-2a/LAT1 axis in neurons can be implicated in the modulation of mTORC1-dependent neuronal function under physiological and pathological conditions. In any case, LAT1 (Slc7a5) expressed in neurons may be a target for the discovery and development of novel therapeutic agents against various neurodegenerative and neuropsychiatric diseases.
